Back to Search
Start Over
Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in the Danish Multiple Sclerosis Registry
- Source :
- Papp, V, Buron, M D, Siersma, V, Rasmussen, P V, Illes, Z, Kant, M, Hilt, C, Mezei, Z, Roshanisefat, H, Sejbæk, T, Weglewski, A, Van Wingerden, J, Geertsen, S S, Bramow, S, Sellebjerg, F & Magyari, M 2021, ' Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in the Danish Multiple Sclerosis Registry ', PLOS ONE, vol. 16, no. 5, e0250820 . https://doi.org/10.1371/journal.pone.0250820, PLoS ONE, Vol 16, Iss 5, p e0250820 (2021), Papp, V, Buron, M D, Siersma, V, Rasmussen, P V, Illes, Z, Kant, M, Hilt, C, Mezei, Z, Roshanisefat, H, Sejbaek, T, Weglewski, A, van Wingerden, J, Geertsen, S S, Bramow, S, Sellebjerg, F & Magyari, M 2021, ' Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry ', PLoS ONE, vol. 16, no. 5, 0250820 . https://doi.org/10.1371/journal.pone.0250820, PLoS ONE, Papp, V, Buron, M D, Siersma, V, Rasmussen, P V, Illes, Z, Kant, M, Hilt, C, Mezei, Z, Roshanisefat, H, Sejbæk, T, Weglewski, A, van Wingerden, J, Geertsen, S S, Bramow, S, Sellebjerg, F & Magyari, M 2021, ' Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry ', PLOS ONE, vol. 16, no. 5, e0250820 . https://doi.org/10.1371/journal.pone.0250820
- Publication Year :
- 2021
-
Abstract
- Objective Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a population-based large cohort of unselected patients enrolled in The Danish Multiple Sclerosis Registry (DMSR) who started teriflunomide treatment between 2013–2019. Methods This was a complete nationwide population-based cohort study with prospectively enrolled unselected cases. Demographic and disease-specific patient parameters related to treatment history, efficacy outcomes, and discontinuation and switching rates among other clinical variables were assessed at baseline and during follow-up visits. Results A total of 3239 patients (65.4% female) started treatment with teriflunomide during the study period, 56% of whom were treatment-naïve. Compared to previously treated patients, treatment-naïve patients were older on average at disease onset, had a shorter disease duration, a lower Expanded Disability Status Scale score at teriflunomide treatment start and more frequently experienced a relapse in the 12 months prior to teriflunomide initiation. In the 3001 patients initiating teriflunomide treatment at least 12 months before the cut-off date, 72.7% were still on treatment one year after treatment start. Discontinuations in the first year were due mainly to adverse events (15.6%). Over the full follow-up period, 47.5% of patients discontinued teriflunomide treatment. Sixty-three percent of the patients treated with teriflunomide for 5 years were relapse-free, while significantly more treatment-naïve versus previously treated patients experienced a relapse during the follow-up (p Conclusions Solid efficacy and treatment persistence data consistent with other real-world studies were obtained over the treatment period. Treatment outcomes in this real-world scenario of the population-based cohort support previous findings that teriflunomide is an effective and generally well-tolerated DMT for relapsing MS patients with mild to moderate disease activity.
- Subjects :
- Male
European People
Epidemiology
Denmark
ORAL TERIFLUNOMIDE
Hydroxybutyrates
Biochemistry
Geographical locations
Diagnostic Radiology
Cohort Studies
chemistry.chemical_compound
DOUBLE-BLIND
Medical Conditions
Teriflunomide
Medicine and Health Sciences
Ethnicities
REPORTED OUTCOMES
Registries
TREATMENT DECISIONS
education.field_of_study
RELAPSING FORMS
Multidisciplinary
Radiology and Imaging
Neurodegenerative Diseases
Middle Aged
Magnetic Resonance Imaging
Europe
Treatment Outcome
Neurology
TOWER
Research Design
Crotonates
Cohort
DISEASE-MODIFYING THERAPIES
Medicine
Female
TRIAL
Immunosuppressive Agents
Research Article
Cohort study
Adult
medicine.medical_specialty
Multiple Sclerosis
Toluidines
Clinical Research Design
Imaging Techniques
Science
Immunology
Population
Research and Analysis Methods
Autoimmune Diseases
AGE
Diagnostic Medicine
Internal medicine
Nitriles
medicine
Humans
European Union
Adverse effect
education
Danish People
Expanded Disability Status Scale
business.industry
Multiple sclerosis
Biology and Life Sciences
Proteins
medicine.disease
Demyelinating Disorders
Discontinuation
chemistry
Medical Risk Factors
Clinical Immunology
Population Groupings
Adverse Events
Interferons
Clinical Medicine
People and places
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Papp, V, Buron, M D, Siersma, V, Rasmussen, P V, Illes, Z, Kant, M, Hilt, C, Mezei, Z, Roshanisefat, H, Sejbæk, T, Weglewski, A, Van Wingerden, J, Geertsen, S S, Bramow, S, Sellebjerg, F & Magyari, M 2021, ' Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in the Danish Multiple Sclerosis Registry ', PLOS ONE, vol. 16, no. 5, e0250820 . https://doi.org/10.1371/journal.pone.0250820, PLoS ONE, Vol 16, Iss 5, p e0250820 (2021), Papp, V, Buron, M D, Siersma, V, Rasmussen, P V, Illes, Z, Kant, M, Hilt, C, Mezei, Z, Roshanisefat, H, Sejbaek, T, Weglewski, A, van Wingerden, J, Geertsen, S S, Bramow, S, Sellebjerg, F & Magyari, M 2021, ' Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry ', PLoS ONE, vol. 16, no. 5, 0250820 . https://doi.org/10.1371/journal.pone.0250820, PLoS ONE, Papp, V, Buron, M D, Siersma, V, Rasmussen, P V, Illes, Z, Kant, M, Hilt, C, Mezei, Z, Roshanisefat, H, Sejbæk, T, Weglewski, A, van Wingerden, J, Geertsen, S S, Bramow, S, Sellebjerg, F & Magyari, M 2021, ' Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry ', PLOS ONE, vol. 16, no. 5, e0250820 . https://doi.org/10.1371/journal.pone.0250820
- Accession number :
- edsair.doi.dedup.....3a475a534c4fb6343b177993f437df9c